Effectiveness of bevacizumab biosimilars in the treatment of pulmonary diseases

Abstract

Biosimilars have emerged as viable cost-effective therapeutic alternatives to the original high-cost biologics in oncology. This research focuses on biosimilars' roles in pulmonology, diving into non-small cell lung cancer. Central to this is bevacizumab, a monoclonal antibody biosimilar that works by targeting the root cause of tumor spread by vascular metastasis through inhibiting vascular endothelial growth factor, suppressing angiogenesis. The FDA-approved biosimilars (bevacizumab-awwb and bevacizumab-bvzr) demonstrate similar efficacy, safety, and immunogenic profiles modeled after their well-worked predecessors when compared to the original therapeutic agents. Our review also aimed to explain the role of tumor necrosis factor-inhibitor biosimilars such as etanercept, which are used to counteract autoimmune conditions regarding inflammation, and are studied for their inherent properties in treating cancers. Clinical trials show that these agents play supportive roles in inflammation, a central symptom amongst patients with cancer. Survival and placebo data support the success of these biosimilars in desirable medical outcomes. Although adverse effects of the use of biosimilars arise, such as interstitial lung disease, these issues are examined by case studies and comparisons. By integrating clinical evidence, regulatory mechanisms, and pharmacologic/immunogenic profiles, this review expands on the role of biosimilars towards their increased acceptance as viable therapeutic agents.